Fuchs' Corneal Endothelial Dystrophy (FCED)Phase 1/2SPIFD-101NCT02653391
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)
A Phase 1/2 study testing Part A Elamipretide 1.0% Ophthalmic Solution and Part B Elamipretide 3.0% Ophthalmic Solution in people with Fuchs' Corneal Endothelial Dystrophy (FCED), run by Stealth BioTherapeutics Inc. at 2 sites in United States.
Trial summary
This is a Phase 1/2 prospective, randomized, double-masked, and vehicle-controlled trial in two parts to evaluate the safety, tolerability, and efficacy of elamipretide topical ophthalmic solution in patients with Fuchs' Corneal Endothelial Dystrophy (FCED) presenting with mild to moderate corneal edema. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Fuchs' Corneal Endothelial Dystrophy (FCED)
- What is being tested?
- Part A Elamipretide 1.0% Ophthalmic Solution and Part B Elamipretide 3.0% Ophthalmic Solution
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 22 participants
- Where
- 2 sitesUnited States
- Study dates
- Feb 2016to Dec 2018
- Phase
- Phase 1/2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults ≥18 years old at the time of Screening Visit
- Diagnosis of FCED OU (both eyes) based on clinical and ophthalmic test findings
- Clinical evidence of corneal edema OU diagnosed with FCED, including one or more of the following signs: corneal epithelial microcysts, corneal epithelial bullae, stromal folds, or stromal haze
- Central corneal thickness of 550 μm to 700 μm (inclusive) in at least one eye diagnosed with FCED, as measured by ultrasonic pachymetry at the time of Screening Visit and Baseline Visit
- Best-corrected distance visual acuity (BCVA) of 20/25 to 20/320 (inclusive) at the time of Screening Visit and Baseline Visit OU
- Women of childbearing potential must agree to use birth control as specified in the protocol from the date they sign the informed consent form (ICF) until after the last study
- Able to give informed consent and willing to comply with all study visits and examinations
- Part B only: The presence of central endothelium, as determined by the investigator, with an area of contiguous endothelial cells within 1 mm of the central cornea as measured by confocal laser scanning microscopy (CLSM) or specular microscopy at the time of Screening Visit
Who cannot join
- Corneal findings of any type (including, but not limited to, stromal haze or stromal scarring), in either eye, that, based on investigator's assessment, limit the probability of visual improvement after corneal deturgescence
- Any ocular pathology requiring treatment with topical ophthalmic drops, with the exception of glaucoma or ocular hypertension
- Use of topical hypertonic saline drops for 3 days prior to Screening and throughout the duration of the study
- History of corneal disease (other than FCED) or corneal surgery in either eye
- Current use or likely need for the use of contact lens at any time during the study
- History of previous corneal or anterior segment surgery such as LASIK, photorefractive keratectomy, endothelial keratoplasty, penetrating keratoplasty cataract surgery or glaucoma surgery.
Show all 11Show fewer
- Any disease or medical condition that in the opinion of the investigator would prevent the subject from participating in the study or might confound study results
- Participation in other investigational drug or device clinical trials within 30 days prior to enrollment, or planning to participate in any other investigational drug or device clinical trials within 30 days of study completion
- Women who are pregnant or lactating
- Part B only: Participation in Part A of SPIFD-101
- Other protocol-defined inclusion/exclusion criteria may apply.
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Ophthalmic Consultants of Boston
Boston, Massachusetts, 02114
Cincinnati Eye Institute
Edgewood, Kentucky, 41017
About this study
Official title: Part A: a Prospective, Randomized, Double-masked, Vehicle Controlled, Paired-eye Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide Topical Ophthalmic Solution in Subjects With Fuchs' Corneal Endothelial Dystrophy (FCED) Presenting With Mild to Moderate Corneal Edema Part B: a Prospective, Randomized, Double-masked, Vehicle Controlled, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution in Subjects With FCED Presenting With Mild to Moderate Corneal Edema.
This is a Phase 1/2 prospective, randomized, double-masked, and vehicle-controlled trial in two parts to evaluate the safety, tolerability, and efficacy of elamipretide topical ophthalmic solution in patients with Fuchs' Corneal Endothelial Dystrophy (FCED) presenting with mild to moderate corneal edema.
Read the detailed description
This is a Phase 1/2 trial in two parts. Part A is a prospective, randomized, double-masked, vehicle controlled, paired-eye study in approximately 16 subjects to evaluate safety, tolerability and efficacy of elamipretide 1.0% topical ophthalmic solution in patients with Fuchs' Corneal Endothelial Dystrophy (FCED) presenting with mild to moderate corneal edema. Part B is a prospective, randomized double-masked, vehicle controlled study in approximately 11 subjects to evaluate safety, tolerability, and efficacy of elamipretide 3.0% topical ophthalmic solution in patients with FCED presenting with mild to moderate corneal edema.
- Being tested
- Part A Elamipretide 1.0% Ophthalmic Solution, Part B Elamipretide 3.0% Ophthalmic Solution, Part A Placebo, Part B Placebo
- Keywords
- Fuchs' Corneal Endothelial Dystrophy, FCED, Ocuvia™, MTP-131
- Medical subject headings
- Fuchs' Endothelial Dystrophy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Part A Elamipretide 1.0% Ophthalmic SolutionDrug
Also called MTP-131, Bendavia
Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye.
Part B Elamipretide 3.0% Ophthalmic SolutionDrug
Also called MTP-131, Bendavia
Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both eyes.
Part A PlaceboDrug
Part A Each subject will receive one drop of vehicle ophthalmic solution BID in the paired eye of the randomly selected study eye.
Part B PlaceboDrug
Part B: Each subject will receive one drop of vehicle ophthalmic solution BID in both eyes.
| Study group | Role | What they receive |
|---|---|---|
| Elamipretide 1.0% Ophthalmic Solution Part A (Cohort 1) | Experimental | Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye (Cohort 1). Receives: Drug: Part A Elamipretide 1.0% Ophthalmic Solution |
| Elamipretide 3.0% Ophthalmic Solution Part B (Cohort 2) | Experimental | Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both the right and left study eyes (Cohort 2). Receives: Drug: Part B Elamipretide 3.0% Ophthalmic Solution |
| Placebo A | Placebo comparator | Part A: Each subject will receive one drop of vehicle solution BID in the paired eye of the randomly selected study eye (Cohort 1). Receives: Drug: Part A Placebo |
| Part B Placebo | Placebo comparator | Part B Each subject will receive one drop of vehicle solution BID in both the right and left study eyes (Cohort 2). Receives: Drug: Part B Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence and Severity of Ocular TEAEs.
The incidence and severity of ocular treatment emergent adverse events (TEAEs)
Measured: Screening Visit, Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16
The Incidence and Severity of Systemic Adverse Events
The incidence and severity of systemic treatment emergent adverse events (TEAEs)
Measured: Screening Visit, Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16
Change From Baseline in Findings From Slit Lamp Examinations (SLE) Part A
Number of participants who had a change from baseline from normal or abnormal not clinically significant, to abnormal clinically significant (CS) findings for slit lamp examinations (SLE) for Part A. Part B is reported as separate outcome since unit of measure is number of eyes.
Measured: Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16
Change From Baseline in Findings From Slit Lamp Examinations (SLE) Part B
Number of eyes with a change from baseline from normal or abnormal not clinically significant, to abnormal clinically significant (CS) findings for slit lamp examinations (SLE) for Part B. Part A is reported as separate outcome.
Measured: Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16
Change From Baseline in Intraocular Pressure (IOP) for Part A
Change from Baseline in intraocular pressure (IOP) using Goldmann applanation tonometry for Part A
Measured: Baseline, Week 1, Week 4, Week 8, Week 12
Change From Baseline in Intraocular Pressure (IOP) for Part B
Change from Baseline in intraocular pressure (IOP) using Goldmann applanation tonometry for Part B. Part A is reported separately.
Measured: Baseline, Week 1, Week 4, Week 8, Week 12 , and Week 16 or early discontinuation visit
Secondary outcomes (18)
Change From Baseline in Central Corneal Thickness by Visit Part A as Measured by Pachymetry for Part A
Change from Baseline in Central Corneal Thickness by Visit as measured by Pachymetry for Part A. Part B is reported as a separate outcome measure.
Measured: Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16
Central Corneal Thickness Part B
Central Corneal Thickness: by-subject data as measured by Pachymetry and Pentacam. Part A is reported as a separate outcome measure.
Measured: Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16, or Early discontinuation visit
Change From Baseline Endothelial Cell Hexagonality in Percentage Over All 12 Weeks for Part A
Change From Baseline in Endothelial Cell Hexagonality in Percentage Over All 12 Weeks for Part A. Specular microscopy is a noninvasive photographic technique that allows visualization and analyzation the corneal endothelium. Using computer-assisted morphometry, specular microscopes analyzes the size, shape and population of the endothelial cells. Histologically, healthy corneal cells initially have a hexagonal shape. As endothelial cells die, neighboring cells enlarge to cover the empty space once occupied by the cell. This, in turn, causes the remaining cells to lose their hexagonal shape. Assessments were performed using the flex center and full auto methods for Part A and data from the flex center method was summarized. The flex center method was used for Part B. The percent of Part B is entered as a separate outcome measure. A decrease from baseline in % cell hexagonality means worse outcome, a increase from baseline means better outcome.
Measured: Baseline, Week 1, 4, 8, and 12
Corneal Endothelial Cell Hexagonality Part B
Corneal Endothelial Cell Hexagonality in Percentage by-subject data: Part B. Data was only listed in weeks where images were good enough quality to quantify. Specular microscopy is a noninvasive photographic technique that allows visualization and analyzation the corneal endothelium. Using computer-assisted morphometry, specular microscopes analyzes the size, shape and population of the endothelial cells. Histologically, healthy corneal cells initially have a hexagonal shape. As endothelial cells die, neighboring cells enlarge to cover the empty space once occupied by the cell. This, in turn, causes the remaining cells to lose their hexagonal shape. The flex center method was used for Part B. A decrease in percent of cell hexagonality from baseline means worse outcome, an increase from baseline means better outcome.
Measured: Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16 or early discontinuation visit
Change From Baseline in Best Corrected Visual Acuity (BCVA) Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale for Part A.
Best corrected visual acuity (BCVA) using the using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale by visit. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome). Part B was listed separately.
Measured: Baseline, Weeks 1, 4, 8, 12, and 16
Best Corrected Visual Acuity (BCVA) Score Using ETDRS Scale for Part B
Best corrected visual acuity (BCVA) using the using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale by visit. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).
Measured: Baseline, Weeks 1, 4, 8, 12, and 16
Change From Baseline in Endothelial Cell Density Over All 12 Weeks for Part A
Change From Baseline in Endothelial Cell Counts, or density (Counts/mm^2) over all 12 weeks for Part A. Part B is entered as a separate outcome measure.
Measured: Baseline, Weeks 1, 4, 8, and 12
Corneal Endothelial Cell Density Part B
Corneal Endothelial Cell Density: Part B, By-subject data for all time points where images were readable. For all time points where there were "Poor Quality Images" or "too few cells to register", there were no data available, and these were not listed below.
Measured: Baseline, Weeks 1, 4, 8, 12, and 16.
Change From Baseline in Endothelial Cell Coefficient of Variation Over All 12 Weeks for Part A
Change From Baseline in Endothelial Cell Coefficient of Variation Over All 12 Weeks. Coefficient of variation (CV) is Standard deviation (SD) of cell area divided by the mean cell area of endothelial cell analyzed. CV represents the coefficient, or degree, of variation in the sizes of the endothelial cells (polymegethism). By measuring the variation in size between endothelial cells, the system can measure how much cell loss is occurring. The more variation, the worse the outcome. Part B is is entered as a separate outcome measure.
Measured: Baseline, Week 12
Coefficient of Variation (CoV) Part B
Part B, By-subject data for all time points where images were readable. For all time points where there were "Poor Quality Images" or "too few cells to register" there were no data available. CoV represents the coefficient, or degree, of variation in the sizes of the endothelial cells. By measuring the variation in size between endothelial cells, the system can measure how much cell loss is occurring. A CoV less than 40 is normal.
Measured: Baseline, Weeks 1, 4, 8,12, and 16
Change From Baseline in Corneal Area Affected by Microcysts for Part A
Change from Baseline in corneal area affected by microcysts by visit for Part A.
Measured: Baseline, Weeks 1, 4, 8, 12, and 16
Corneal Area Affected by Microcysts: Part B
Corneal area affected by microcysts: by-subject data for Part B. No microcysts were present for any timepoints.
Measured: Baseline, Weeks 1, 4, 8, 12, and 16, or early discontinuation visit
Change From Baseline in Corneal Bullae for Part A.
Count of participants in number, size and location of bullae by treatment. Part B is listed separately.
Measured: Baseline, Week 1, Week 4, Week 8, Week 12, Week 16
Corneal Bullae: Part B
Number, size and location of Corneal bullae: By-subject data: Part B.
Measured: Baseline, Week 1, Week 4, Week 8, Week 12, Week 16, or early discontinuation visit
Change From Baseline in Severity of Corneal Stromal Folds for Part A
Change from baseline in severity of corneal stromal folds by visit. Descriptive assessment made by Investigator; severity is not assessed using a scale.
Measured: Baseline, Weeks 1, 4, 8, 12, and 16
Severity of Corneal Stromal Folds:Part B
Severity of corneal stromal folds by-subject data by visit. Descriptive assessment made by Investigator in the following categories: Not present, trace, mild.
Measured: Baseline, Week 1, 4, 8, 12, and 16, or early discontinuation visit
Change From Baseline in Contrast Sensitivity (Log Score) for Part A
Change from Baseline in contrast sensitivity over all 12 weeks log score at 3, 6, 12, 18 cycles per degree (cpd) using Vector Vision's CSV-1000E. Standard tables for the VectorVision's CSV-1000E model were used to convert linear results to the log values. Lower log scores equals lower contrast sensitivity and worse outcome. Higher log scores mean higher contrast sensitivity and better outcome. For 3cpd, range is 0.7-2.08; 6 cpd: 0.91-2.29; 12 cpd: 0.61-1.99; 18cpd: 0.17-1.55, unless no gratings were visible. If no gratings were visible, .3 log was subtracted from the lowest score for 3, 6, and 12cpd. For 18cpd .01 log was used, or essentially 100% contrast.
Measured: Baseline, Week 1, 4, 8, 12 weeks
Contrast Sensitivity for Part B; By-subject Data
Contrast Sensitivity log score at 3, 6, 12, 18 cycles per degree (cpd) using Vector Vision's CSV-1000E by-subject data, Part B. Part A is listed separately. Standard tables for the VectorVision's CSV-1000E model were used to convert linear results to the log values. Lower log scores equals lower contrast sensitivity and worse outcome. Higher log scores mean higher contrast sensitivity and better outcome. For 3cpd, range is 0.7-2.08; 6 cpd: 0.91-2.29; 12 cpd: 0.61-1.99; 18cpd: 0.17-1.55, unless no gratings were visible. If no gratings were visible, .3 log was subtracted from the lowest score for 3, 6, and 12cpd. For 18cpd .01 log was used, or essentially 100% contrast.
Measured: Baseline, Week 1, Week 4, Week 8, Week 12, Week 16, or early discontinuation visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2016 (estimated)
- Study startFeb 2016
- Primary completionMar 2018
- Study completionDec 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Fuchs' Corneal Endothelial Dystrophy (FCED)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 22 participants (actual)
Sponsor and investigators
- Lead sponsor
- Stealth BioTherapeutics Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Michael Raizman, MD, Principal investigator, Ophthalmic Consultants of BostonEdward Holland, MD, Principal investigator, Cincinnati Eye Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02653391
- Sponsor's protocol ID
- SPIFD-101
- Acronym
- SPIFD-101
- Status last verified
- Aug 2021
- First submitted
- 20 Dec 2015
- Last updated
- 17 Sep 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Part A: a Prospective, Randomized, Double-masked, Vehicle Controlled, Paired-eye Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide Topical Ophthalmic Solution in Subjects With Fuchs' Corneal Endothelial Dystrophy (FCED) Presenting With Mild to Moderate Corneal Edema Part B: a Prospective, Randomized, Double-masked, Vehicle Controlled, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution in Subjects With FCED Presenting With Mild to Moderate Corneal Edema.
- ClinicalTrials.gov ID
- NCT02653391
- Acronym / sponsor ID
- SPIFD-101 / SPIFD-101
- Keywords
- Fuchs' Corneal Endothelial Dystrophy, FCED, Ocuvia™, MTP-131
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 22 participants (actual)
- Lead sponsor
- Stealth BioTherapeutics Inc.Industry (pharma, biotech, devices)
- Study start
- Feb 2016 (actual)
- Primary completion
- Mar 2018 (actual)
- Study completion
- Dec 2018 (actual)
- First posted
- 12 Jan 2016 (estimated)
- Results
- Posted 17 Sep 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Phase 1/2 prospective, randomized, double-masked, and vehicle-controlled trial in two parts to evaluate the safety, tolerability, and efficacy of elamipretide topical ophthalmic solution in patients with Fuchs' Corneal Endothelial Dystrophy (FCED) presenting with mild to moderate corneal edema.
Detailed description
This is a Phase 1/2 trial in two parts. Part A is a prospective, randomized, double-masked, vehicle controlled, paired-eye study in approximately 16 subjects to evaluate safety, tolerability and efficacy of elamipretide 1.0% topical ophthalmic solution in patients with Fuchs' Corneal Endothelial Dystrophy (FCED) presenting with mild to moderate corneal edema. Part B is a prospective, randomized double-masked, vehicle controlled study in approximately 11 subjects to evaluate safety, tolerability, and efficacy of elamipretide 3.0% topical ophthalmic solution in patients with FCED presenting with mild to moderate corneal edema.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Elamipretide 1.0% Ophthalmic Solution Part A (Cohort 1) | Experimental | Drug: Part A Elamipretide 1.0% Ophthalmic SolutionPart A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye (Cohort 1). |
| Elamipretide 3.0% Ophthalmic Solution Part B (Cohort 2) | Experimental | Drug: Part B Elamipretide 3.0% Ophthalmic SolutionPart B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both the right and left study eyes (Cohort 2). |
| Placebo A | Placebo comparator | Drug: Part A PlaceboPart A: Each subject will receive one drop of vehicle solution BID in the paired eye of the randomly selected study eye (Cohort 1). |
| Part B Placebo | Placebo comparator | Drug: Part B PlaceboPart B Each subject will receive one drop of vehicle solution BID in both the right and left study eyes (Cohort 2). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Adults ≥18 years old at the time of Screening Visit
- Diagnosis of FCED OU (both eyes) based on clinical and ophthalmic test findings
- Clinical evidence of corneal edema OU diagnosed with FCED, including one or more of the following signs: corneal epithelial microcysts, corneal epithelial bullae, stromal folds, or stromal haze
- Central corneal thickness of 550 μm to 700 μm (inclusive) in at least one eye diagnosed with FCED, as measured by ultrasonic pachymetry at the time of Screening Visit and Baseline Visit
- Best-corrected distance visual acuity (BCVA) of 20/25 to 20/320 (inclusive) at the time of Screening Visit and Baseline Visit OU
Key exclusion criteria (11 listed)
- Corneal findings of any type (including, but not limited to, stromal haze or stromal scarring), in either eye, that, based on investigator's assessment, limit the probability of visual improvement after corneal deturgescence
- Any ocular pathology requiring treatment with topical ophthalmic drops, with the exception of glaucoma or ocular hypertension
- Use of topical hypertonic saline drops for 3 days prior to Screening and throughout the duration of the study
- History of corneal disease (other than FCED) or corneal surgery in either eye
- Current use or likely need for the use of contact lens at any time during the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Part A Elamipretide 1.0% Ophthalmic SolutionAlso: MTP-131, BendaviaPart A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye. | Drug | Elamipretide 1.0% Ophthalmic Solution Part A (Cohort 1) |
| Part B Elamipretide 3.0% Ophthalmic SolutionAlso: MTP-131, BendaviaPart B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both eyes. | Drug | Elamipretide 3.0% Ophthalmic Solution Part B (Cohort 2) |
| Part A PlaceboPart A Each subject will receive one drop of vehicle ophthalmic solution BID in the paired eye of the randomly selected study eye. | Drug | Placebo A |
| Part B PlaceboPart B: Each subject will receive one drop of vehicle ophthalmic solution BID in both eyes. | Drug | Part B Placebo |
Primary outcome
Incidence and Severity of Ocular TEAEs.
Time frame: Screening Visit, Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16
The incidence and severity of ocular treatment emergent adverse events (TEAEs)
The Incidence and Severity of Systemic Adverse Events
Time frame: Screening Visit, Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16
The incidence and severity of systemic treatment emergent adverse events (TEAEs)
Change From Baseline in Findings From Slit Lamp Examinations (SLE) Part A
Time frame: Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16
Number of participants who had a change from baseline from normal or abnormal not clinically significant, to abnormal clinically significant (CS) findings for slit lamp examinations (SLE) for Part A. Part B is reported as separate outcome since unit of measure is number of eyes.
Change From Baseline in Findings From Slit Lamp Examinations (SLE) Part B
Time frame: Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16
Number of eyes with a change from baseline from normal or abnormal not clinically significant, to abnormal clinically significant (CS) findings for slit lamp examinations (SLE) for Part B. Part A is reported as separate outcome.
Change From Baseline in Intraocular Pressure (IOP) for Part A
Time frame: Baseline, Week 1, Week 4, Week 8, Week 12
Change from Baseline in intraocular pressure (IOP) using Goldmann applanation tonometry for Part A
Change From Baseline in Intraocular Pressure (IOP) for Part B
Time frame: Baseline, Week 1, Week 4, Week 8, Week 12 , and Week 16 or early discontinuation visit
Change from Baseline in intraocular pressure (IOP) using Goldmann applanation tonometry for Part B. Part A is reported separately.
18 secondary outcomes
Change From Baseline in Central Corneal Thickness by Visit Part A as Measured by Pachymetry for Part A
Time frame: Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16
Central Corneal Thickness Part B
Time frame: Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16, or Early discontinuation visit
Change From Baseline Endothelial Cell Hexagonality in Percentage Over All 12 Weeks for Part A
Time frame: Baseline, Week 1, 4, 8, and 12
Corneal Endothelial Cell Hexagonality Part B
Time frame: Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16 or early discontinuation visit
Change From Baseline in Best Corrected Visual Acuity (BCVA) Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale for Part A.
Time frame: Baseline, Weeks 1, 4, 8, 12, and 16
Best Corrected Visual Acuity (BCVA) Score Using ETDRS Scale for Part B
Time frame: Baseline, Weeks 1, 4, 8, 12, and 16
Change From Baseline in Endothelial Cell Density Over All 12 Weeks for Part A
Time frame: Baseline, Weeks 1, 4, 8, and 12
Corneal Endothelial Cell Density Part B
Time frame: Baseline, Weeks 1, 4, 8, 12, and 16.
Change From Baseline in Endothelial Cell Coefficient of Variation Over All 12 Weeks for Part A
Time frame: Baseline, Week 12
Coefficient of Variation (CoV) Part B
Time frame: Baseline, Weeks 1, 4, 8,12, and 16
Change From Baseline in Corneal Area Affected by Microcysts for Part A
Time frame: Baseline, Weeks 1, 4, 8, 12, and 16
Corneal Area Affected by Microcysts: Part B
Time frame: Baseline, Weeks 1, 4, 8, 12, and 16, or early discontinuation visit
Change From Baseline in Corneal Bullae for Part A.
Time frame: Baseline, Week 1, Week 4, Week 8, Week 12, Week 16
Corneal Bullae: Part B
Time frame: Baseline, Week 1, Week 4, Week 8, Week 12, Week 16, or early discontinuation visit
Change From Baseline in Severity of Corneal Stromal Folds for Part A
Time frame: Baseline, Weeks 1, 4, 8, 12, and 16
Severity of Corneal Stromal Folds:Part B
Time frame: Baseline, Week 1, 4, 8, 12, and 16, or early discontinuation visit
Change From Baseline in Contrast Sensitivity (Log Score) for Part A
Time frame: Baseline, Week 1, 4, 8, 12 weeks
Contrast Sensitivity for Part B; By-subject Data
Time frame: Baseline, Week 1, Week 4, Week 8, Week 12, Week 16, or early discontinuation visit
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Sep 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael Raizman, MD principal investigator
Ophthalmic Consultants of Boston
Edward Holland, MD principal investigator
Cincinnati Eye Institute
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing Part A Elamipretide 1.0% Ophthalmic Solution and Part B Elamipretide 3.0% Ophthalmic Solution in people with Fuchs' Corneal Endothelial Dystrophy (FCED), run by Stealth BioTherapeutics Inc. at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 17 Sep 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence and Severity of Ocular TEAEs. (time frame: Screening Visit, Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2021.